

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review.....	11
4. Data for the <i>Monographs</i>	12
5. Meeting participants.....	12
6. Working procedures.....	13
B. SCIENTIFIC REVIEW AND EVALUATION	14
1. Exposure data.....	15
2. Studies of cancer in humans.....	16
3. Studies of cancer in experimental animals.....	20
4. Mechanistic and other relevant data.....	23
5. Summary.....	26
6. Evaluation and rationale.....	27
References.....	31
GENERAL REMARKS	33
High production volume chemicals and exposure measurement data.....	33
Isoniazid.....	33
Disruption of the thyroid hormone pathway.....	34
Evaluation of data on the mechanisms of cancer.....	34
References.....	34

1-BROMOPROPANE	37
1. Exposure Data	37
1.1 Identification of the agent	37
1.2 Production and use	38
1.3 Measurement and analysis	38
1.4 Occurrence and exposure	40
1.5 Regulations and guidelines	47
2. Cancer in Humans	47
3. Cancer in Experimental Animals	47
3.1 Mouse	47
3.2 Rat	50
4. Mechanistic and Other Relevant Data	51
4.1 Absorption, distribution, metabolism, excretion	51
4.2 Mechanisms of carcinogenesis	53
4.3 Data relevant to comparisons across agents and end-points	60
4.4 Susceptibility to cancer	64
4.5 Other adverse effects	65
5. Summary of Data Reported	66
5.1 Exposure data	66
5.2 Human carcinogenicity data	66
5.3 Animal carcinogenicity data	66
5.4 Mechanistic and other relevant data	66
6. Evaluation	67
6.1 Cancer in humans	67
6.2 Cancer in experimental animals	67
6.3 Overall evaluation	67
References	67
2-MERCAPTOBENZOTHAZOLE	73
1. Exposure Data	73
1.1 Identification of the agent	73
1.2 Production and use	73
1.3 Measurement and analysis	74
1.4 Occurrence and exposure	74
1.5 Regulations and guidelines	79
2. Cancer in Humans	80
3. Cancer in Experimental Animals	85
3.1 Mouse	85
3.2 Rat	89
4. Mechanistic and Other Relevant Data	90
4.1 Absorption, distribution, metabolism, excretion	90
4.2 Mechanisms of carcinogenesis	91
4.3 Data relevant to comparisons across agents and end-points	94
4.4 Susceptibility to cancer	94
4.5 Other adverse effects	94

5. Summary of Data Reported	95
5.1 Exposure data	95
5.2 Human carcinogenicity data	96
5.3 Animal carcinogenicity data	96
5.4 Mechanistic and other relevant data	96
6. Evaluation	97
6.1 Cancer in humans	97
6.2 Cancer in experimental animals	97
6.3 Overall evaluation	97
References	97
3-CHLORO-2-METHYLPROPENE	103
1. Exposure Data	103
1.1 Identification of the agent	103
1.2 Production and use	104
1.3 Measurement and analysis	104
1.4 Occurrence and exposure	104
1.5 Regulations and guidelines	105
2. Cancer in Humans	105
3. Cancer in Experimental Animals	105
3.1 Mouse	105
3.2 Rat	111
4. Mechanistic and Other Relevant Data	112
4.1 Absorption, distribution, metabolism, excretion	112
4.2 Mechanisms of carcinogenesis	113
4.3 Data relevant to comparisons across agents and end-points	115
4.4 Susceptibility to cancer	115
4.5 Other adverse effects	115
5. Summary of Data Reported	115
5.1 Exposure data	115
5.2 Human carcinogenicity data	115
5.3 Animal carcinogenicity data	115
5.4 Mechanistic and other relevant data	116
6. Evaluation	116
6.1 Cancer in humans	116
6.2 Cancer in experimental animals	117
6.3 Overall evaluation	117
References	117
<i>N,N</i>-DIMETHYLFORMAMIDE	119
1. Exposure Data	119
1.1 Identification of the agent	119
1.2 Production and use	120
1.3 Measurement and analysis	120
1.4 Occurrence and exposure	121
1.5 Regulations and guidelines	127

2. Cancer in Humans	128
2.1 Aircraft repair	128
2.2 Leather workers	132
2.3 Chemical manufacturing	132
3. Cancer in Experimental Animals	135
3.1 Mouse	135
3.2 Rat	139
4. Mechanistic and Other Relevant Data	141
4.1 Absorption, distribution, metabolism, excretion	141
4.2 Mechanisms of carcinogenesis	147
4.3 Data relevant to comparisons across agents and end-points	158
4.4 Susceptibility to cancer	158
4.5 Other adverse effects	158
5. Summary of Data Reported	159
5.1 Exposure data	159
5.2 Human carcinogenicity data	159
5.3 Animal carcinogenicity data	160
5.4 Mechanistic and other relevant data	161
6. Evaluation	161
6.1 Cancer in humans	161
6.2 Cancer in experimental animals	161
6.3 Overall evaluation	161
References	162
<i>N,N</i>-DIMETHYL-<i>P</i>-TOLUIDINE	171
1. Exposure Data	171
1.1 Identification of the agent	171
1.2 Production and use	171
1.3 Measurement and analysis	172
1.4 Occurrence and exposure	172
1.5 Regulations and guidelines	173
2. Cancer in Humans	174
3. Cancer in Experimental Animals	174
3.1 Mouse	174
3.2 Rat	178
4. Mechanistic and Other Relevant Data	180
4.1 Absorption, distribution, metabolism, excretion	180
4.2 Mechanisms of carcinogenesis	181
4.3 Data relevant to comparisons across agents and end-points	184
4.4 Susceptibility to cancer	184
4.5. Other adverse effects	184
5. Summary of Data Reported	185
5.1 Exposure data	185
5.2 Human carcinogenicity data	185
5.3 Animal carcinogenicity data	185
5.4 Mechanistic and other relevant data	186

6. Evaluation.....	186
6.1 Cancer in humans.....	186
6.2 Cancer in experimental animals.....	186
6.3 Overall evaluation.....	187
References.....	187
HYDRAZINE.....	191
1. Exposure Data.....	191
1.1 Identification of the agent.....	191
1.2 Production and use.....	192
1.3 Measurement and analysis.....	193
1.4 Occurrence and exposure.....	193
1.5 Regulations and guidelines.....	198
2. Cancer in Humans.....	199
3. Cancer in Experimental Animals.....	205
3.1 Mouse.....	205
3.2 Rat.....	224
3.3 Hamster.....	225
4. Mechanistic and Other Relevant Data.....	227
4.1 Absorption, distribution, metabolism, excretion.....	227
4.2 Mechanisms of carcinogenesis.....	230
4.3 Data relevant to comparisons across agents and end-points.....	236
4.4 Cancer susceptibility.....	236
4.5 Other adverse effects.....	236
5. Summary of Data Reported.....	236
5.1 Exposure data.....	236
5.2 Human carcinogenicity data.....	237
5.3 Animal carcinogenicity data.....	237
5.4 Mechanistic and other relevant data.....	238
6. Evaluation.....	239
6.1 Cancer in humans.....	239
6.2 Cancer in experimental animals.....	239
6.3 Overall evaluation.....	239
References.....	239
TETRABROMOBISPHENOLA.....	247
1. Exposure Data.....	247
1.1. Identification of the agent.....	247
1.2 Production and use.....	248
1.3 Measurement and analysis.....	249
1.4 Occurrence and exposure.....	252
1.5 Regulations and guidelines.....	258
2. Cancer in Humans.....	258

3. Cancer in Experimental Animals	258
3.1 Mouse	258
3.2 Rat	261
3.3 Co-carcinogenicity	263
4. Mechanistic and Other Relevant Data	264
4.1 Absorption, distribution, metabolism, excretion	264
4.2 Mechanisms of carcinogenesis	266
4.3 Data relevant to comparisons across agents and end-points	277
4.4 Susceptibility to cancer	277
4.5 Other adverse effects	277
5. Summary of Data Reported	278
5.1 Exposure data	278
5.2 Human carcinogenicity data	278
5.3. Animal carcinogenicity data	278
5.4 Mechanistic and other relevant data	278
6. Evaluation	279
6.1 Cancer in humans	279
6.2 Cancer in experimental animals	279
6.3 Overall evaluation	280
6.4 Rationale	280
References	280

LIST OF ABBREVIATIONS	291
------------------------------------	------------

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.

